首页> 外文期刊>Cell death and differentiation >The adenine nucleotide translocator 1 acts as a type 2 transglutaminase substrate: implications for mitochondrial-dependent apoptosis.
【24h】

The adenine nucleotide translocator 1 acts as a type 2 transglutaminase substrate: implications for mitochondrial-dependent apoptosis.

机译:腺嘌呤核苷酸转运蛋白1充当2型转谷氨酰胺酶底物:对线粒体依赖性细胞凋亡的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

In this study we provide in vitro and in vivo evidence showing that the protein disulphide isomerase (PDI) activity of type 2 transglutaminase (TG2) regulates the correct assembly and function of the mitochondrial ADP/ATP transporter adenine nucleotide translocator 1 (ANT1). We demonstrate, by means of biochemical and morphological analyses, that ANT1 and TG2 physically interact in the mitochondria. Under physiological conditions, TG2's PDI activity regulates the ADP/ATP transporter function by controlling the oligomerization of ANT1. In fact, mitochondria isolated from hearts of TG2(-/-) mice exhibit increased polymerization of ANT1, paralleled by an enhanced ADP/ATP carrier activity, as compared to mitochondria belonging to TG2(+/+) mice. Interestingly, upon cell-death induction, ANT1 becomes a substrate for TG2's cross-linking activity and the lack of TG2 results in a reduction of apoptosis as well as in a marked sensitivity to the ADP/ATP exchange inhibition by atractyloside. These findings suggest a complex TG2-dependent regulation of the ADP/ATP transporter and reveal new important avenues for its potential applications in the treatment of some mitochondrial-dependent diseases, including cardiovascular and neurodegenerative diseases.
机译:在这项研究中,我们提供了体外和体内的证据,表明2型转谷氨酰胺酶(TG2)的蛋白质二硫键异构酶(PDI)活性调节线粒体ADP / ATP转运腺嘌呤核苷酸转运蛋白1(ANT1)的正确装配和功能。我们通过生化和形态分析证明,ANT1和TG2在线粒体中发生物理相互作用。在生理条件下,TG2的PDI活性通过控制ANT1的寡聚来调节ADP / ATP转运蛋白的功能。实际上,与属于TG2(+ / +)小鼠的线粒体相比,从TG2(-/-)小鼠心脏分离的线粒体显示出ANT1的聚合增加,同时具有增强的ADP / ATP载体活性。有趣的是,在细胞死亡诱导后,ANT1成为TG2交联活性的底物,而TG2的缺乏导致凋亡的减少以及对白术苷对ADP / ATP交换抑制的显着敏感性。这些发现表明对ADP / ATP转运蛋白的依赖于TG2的复杂调节,并揭示了其潜在用途在治疗某些线粒体依赖性疾病(包括心血管疾病和神经退行性疾病)中的新的重要途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号